Surmodics IVD Launches Breakthrough StabilBlock® Immunoassay Stabilizer
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 1, 2016--
Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components
for in vitro diagnostic (IVD) tests and microarrays, has announced the
launch and immediate availability of StabilBlock®, its most
advanced Immunoassay Stabilizer. StabilBlock Immunoassay Stabilizer is
the best available reagent for reducing non-specific binding to boost
immunoassay signal-to-noise ratios.
Surmodics offers a family of immunoassay stabilizers, which preserve the
conformation and activity of dried proteins on a wide range of surfaces,
keeping antibodies and antigens at peak performance for long durations.
At the same time, the blocking mechanisms in these reagents reduce
non-specific binding of interfering proteins to maximize assay
sensitivity. With StabilBlock, StabilCoat® and StabilGuard®
Immunoassay Stabilizers, the company now offers three options to assay
developers with a combination of blocking efficacy and long-term dried
stability that is unmatched in the industry.
“As part of our commitment to being the premier provider of IVD assay
components to improve performance and manufacturability of immunoassays,
we continue to advance our offerings to meet the needs of our
customers,” said Joe Stich, vice president and general manager of
Surmodics IVD, the company’s In Vitro Diagnostics business. “We
recognize that each assay has its own blocking requirements and our
expanded portfolio of Immunoassay Stabilizers will enable assay
developers to achieve the best results for each application.”
Surmodics IVD products immediately improve assay performance and
manufacturability of assays by lowering backgrounds, increasing signal
generation and providing longer shelf lives for immunoassay production.
The addition of StabilBlock Immunoassay Stabilizer augments the
company’s leading portfolio of products, including:
The StabilZyme® family provides unparalleled long-term
stability of protein conjugates at working strength concentrations.
Surmodics formulations for HRP conjugates, AP conjugates and general
protein applications ensure that assay developers have a complete set
of tools to address the labile nature of each protein of interest.
BioFX® TMB substrate family outperforms competitors for low
background, stability and sensitivity with a variety of kinetic rate
substrates. The one-component formulations provide optimal signal
generation and longer shelf lives.
Assay Diluent (Protein-Free) normalizes the sample matrix and reduces
interference to ensure that analyte-specific signal is generated
within an assay system.
About Surmodics, Inc.
Surmodics is the global leader in
surface modification technologies for intravascular medical devices and
a leading provider of chemical components for in vitro diagnostic (IVD)
tests and microarrays. Following two recent acquisitions of Creagh
Medical and NorMedix, the company is executing a key growth strategy for
its medical device business by expanding to offer total intravascular
product solutions to its medical device customers. The combination of
proprietary surface technologies, along with enhanced device design,
development and manufacturing capabilities, enables Surmodics to
significantly increase the value it offers with highly differentiated
intravascular solutions designed and engineered to meet the most
With this focus on offering total product solutions, Surmodics’ mission
remains to improve the detection and treatment of disease. Surmodics is
headquartered in Eden Prairie, Minnesota. For more information about the
company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005190/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000
Vice President of
Finance and Chief Financial Officer